Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Emilia, D'elia"'
Autor:
Giulio Balestrieri, Raul Limonta, Enrico Ponti, Anna Merlo, Edoardo Sciatti, Salvatore D’Isa, Mauro Gori, Gavino Casu, Cristina Giannattasio, Michele Senni, Emilia D’Elia
Publikováno v:
Cardiac Failure Review, Vol 10, Iss , Pp - (2024)
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterised by the presence of diastolic dysfunction and elevated left ventricular filling pressure, in the setting of a left ventricular ejection fraction of at least 50
Externí odkaz:
https://doaj.org/article/241a376307484ebe87b1d808514d07c0
Autor:
Cosimo A. Stamerra, Emilia D'Elia, Mauro Gori, Federica Roncali, Alberto Cereda, Antonello Gavazzi, Claudio Ferri, Michele Senni
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundHeart failure with preserved ejection fraction (HFpEF) is very frequently associated to sleep breathing disorders (SDB). Red blood cell distribution width (RDW) has been shown to be a potential inflammatory index linked to the degree of hyp
Externí odkaz:
https://doaj.org/article/bf5e2d1a8b8345f4926f8b6c1607ba0f
Publikováno v:
Cardiology Plus, Vol 7, Iss 1, Pp 20-28 (2022)
Abstract. Heart failure with reduced ejection fraction (HFrEF) is a common disease requiring multi-drug therapy. Moreover, it is associated with a poor prognosis, with increasing prevalence in the community. In the last decade, two major drug classes
Externí odkaz:
https://doaj.org/article/cbc95f47feac4fddad4f56982626bb56
Publikováno v:
Cardiac Failure Review, Vol 8, Iss , Pp - (2022)
Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor
Externí odkaz:
https://doaj.org/article/3733938e4b7b43128f22d973d83e4c4b
Autor:
Edoardo Sciatti, Anna Merlo, Claudio Scangiuzzi, Raul Limonta, Mauro Gori, Emilia D’Elia, Alberto Aimo, Giuseppe Vergaro, Michele Emdin, Michele Senni
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 12, p 3970 (2023)
In recent years, there has been growing interest in the risk stratification for heart failure, and the use of multiple biomarkers to identify different pathophysiological processes associated with this condition. One such biomarker is soluble suppres
Externí odkaz:
https://doaj.org/article/07a5de4a82494a599468ff1a2a926fcb
Autor:
Emilia D’Elia, Mauro Gori, Aurelia Grosu, Annamaria Iorio, Ferdinando Luca Lorini, Anna Falanga, Fabiano Di Marco, Michele Senni
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-4 (2021)
Abstract Background Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long ter
Externí odkaz:
https://doaj.org/article/4570569c605d4749b45aa0d760e05b55
Publikováno v:
Cardiology Plus, Vol 6, Iss 1, Pp 23-29 (2021)
Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF). Compared to angiotensin-converting enzy
Externí odkaz:
https://doaj.org/article/56560761138c4de6b4ce1b8308b3405b
Autor:
Stefania Angela Di Fusco, Aldo Pietro Maggioni, Pietro Scicchitano, Marco Zuin, Emilia D’Elia, Furio Colivicchi
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 7, p 2529 (2023)
Growing evidence has shown that high levels of lipoprotein (a) (Lp(a)) and chronic inflammation may be responsible for the residual risk of cardiovascular events in patients managed with an optimal evidence-based approach. Clinical studies have demon
Externí odkaz:
https://doaj.org/article/bb7a43fca2d14b979600ca286bc8a6a3
Autor:
Edoardo Sciatti, Emilia D’Elia, Giulio Balestrieri, Salvatore D’Isa, Attilio Iacovoni, Michele Senni
Publikováno v:
European Heart Journal Supplements. 25:C301-C305
Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It is common in heart failure (HF) patients due to the disease itself, which often co-exists with chronic kidney disease and diabetes mellitus, the fluctuat
Publikováno v:
European Heart Journal Supplements. 25:B140-B143
The 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) have abandoned the sequential approach for optimal drug therapy and propose four drug classes (enzyme inhibitors conversion age